Discovery and clinical development at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
29 organizations at TIDES Europe 2026 present work in discovery & clinical: 23 drug developers, 3 academic, government and non-profit bodies and 3 suppliers and service providers. Between them they bring 41 presentations to the program. Most represented: Novo Nordisk (6 on the program), AstraZeneca (4 on the program), Alnylam Pharmaceuticals (2 on the program). 10 of them have their own page in this guide. As of Sep 25, 2026.
Format
Top represented
Showing 1–14 of 29 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide. | Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Talk Fri Nov 6 12:00–12:25 |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics. | Talk Thu Nov 5 15:00–15:30 Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady. Talk Thu Nov 5 09:05–09:35 Peptide-Targeted Delivery of Oligonucleotide Therapeutics Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act. Talk Thu Nov 5 09:05–09:35 Rethinking Green Credentials for Oligo Manufacturing Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve. Talk Thu Nov 5 08:35–09:05 Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition A way to choose where to split a long peptide into fragments so it can be built in solution with better yield. |
Alnylam Pharmaceuticals Cambridge, MA | |
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases. | Talk Thu Nov 5 15:00–15:30 Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
European Medicines Agency Amsterdam, Netherlands | |
European Union agency that evaluates and supervises medicines, including oligonucleotide and peptide products. | Talk Wed Nov 4 15:00–15:30 EMA Perspectives on mRNA Vaccines and Therapeutics Where European regulators stand on quality rules for mRNA vaccines and medicines, and which problems keep coming up in applications. Talk Wed Nov 4 09:05–09:35 Regulatory Landscape for Synthetic Peptides and Oligonucleotides: EMA Insights and Guideline Updates An update on two draft European guidelines for synthetic peptides and oligonucleotides, the feedback they drew and the problems seen in filings. |
Wave Life Sciences Cambridge, Massachusetts | |
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates. | Talk Wed Nov 4 09:05–09:35 Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney. Talk Thu Nov 5 16:30–17:00 Synthesis and Characterization of Stereopure Chimeric Oligonucleotides Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity. |
Silence Therapeutics London, United Kingdom | |
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases. | Talk Wed Nov 4 10:15–10:45 Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages. |
Spatial biology tools built on RNAscope in situ hybridization and the COMET system: reagents, instruments and software for RNA and protein detection. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 12:50–13:10 Spatially Resolving RNA Therapeutics in Heterogenous Organs: RNAscope to Correlate Biodistribution and Efficacy at Single-Cell Resolution How a tissue staining method shows which individual cells take up an RNA drug and whether it changes gene activity there. OligonucleotidesDiscovery & Clinical |
Catalent Somerset, NJ | |
Contract development and manufacturing organization for drug products, including oral delivery technologies and injectable formulation and fill-finish. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 12:30–12:50 Advancing Beyond Injections: Technologies Driving Oral Delivery of Peptides Ways to get peptide drugs absorbed when swallowed rather than injected, using fatty carriers, slow-release capsules and the lining of the mouth. PeptidesDiscovery & Clinical |
OmniAb Emeryville, California | |
Licenses antibody discovery platforms built on transgenic animals to drug developers. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 09:55–10:05 OmniUltra™: A Dual Modality In Vivo Discovery Platform for Novel Human Antibodies and Structured Peptides How antibodies carrying unusually long loops can reach deep pockets on a target, and how those loops work alone as small peptides. PeptidesDiscovery & Clinical |
A Affilogic Nantes, France | |
Develops Nanofitins, small engineered protein scaffolds used as targeting ligands and therapeutics, including for organ-specific oligonucleotide delivery. | Talk Thu Nov 5 08:05–08:35 Organ Specific Delivery of Oligonucleotides Using Nanofitins How small engineered proteins attached to siRNA carried it into brain and heart muscle in animals and switched off a target gene. |
A AIRNA Cambridge, MA | |
Develops RNA editing medicines, including a GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency. | Talk Wed Nov 4 10:45–11:15 AIR-001: A Highly Potent and Precise GalNAc-conjugated RNA Base Editing Treatment for Alpha-1 Antitrypsin Deficiency Animal results and first-trial progress for an oligonucleotide that corrects the mutation causing alpha-1 antitrypsin deficiency, which damages lung and liver. |
AT Altamira Therapeutics | |
Develops xPhore and related peptide-based platforms for delivering therapeutic nucleic acids such as siRNA and mRNA. | Talk Thu Nov 5 11:15–11:45 xPhore: A Platform for DeLivering Therapeutic Nucleic Acids A peptide that wraps around nucleic acid cargo to form nanoparticles aimed at tumours and inflamed tissue rather than the liver. |
AT Arrakis Therapeutics | |
Develops medicines that target RNA. | Talk Wed Nov 4 11:15–11:45 AIC468, A First-in-class Antisense Oligonucleotide Targeting BKV in Kidney Transplant Patients Animal and early trial safety data on an antisense drug against a virus that can destroy a transplanted kidney. |
Develops intranasally delivered siRNA therapeutics for neuropsychiatric and neurodegenerative disorders. | Talk Thu Nov 5 10:45–11:15 Brain Biodistribution and Neuronal Gene Silencing of Three Intranasally Delivered siRNA Constructs in Rhesus Monkeys Three siRNA designs sprayed into the noses of monkeys reached brain cells along the smell pathway and switched off their target genes. |
Instantly find 20 buyers in discovery & clinical
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TIDES Europe 2026 by
Organization type
Focus
- Oligonucleotides 69
- Peptides 34
- CMC & Manufacturing 56
- Discovery & Clinical 29
- Obesity & Metabolic 9
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction